Kiniksa Pharmaceuticals International KNSA
NASDAQ KNSA
$75.88 +0.65 (+0.87%)
As of: Oct 2, 2026 · 2:30 PM EDT

Kiniksa Pharmaceuticals International (KNSA) Depreciation & Amortization (CF) (2017 - 2026)

Updated

Kiniksa Pharmaceuticals International's Depreciation & Amortization (CF) came in at $472,000 for Q2 2026, up 31.8% from $358,000 a year earlier and up 0.9% from the prior quarter.

Analysis

Kiniksa Pharmaceuticals International (KNSA) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Kiniksa Pharmaceuticals International reported Depreciation & Amortization (CF) of $1.79 million, up 19.2% year-over-year; for FY2025, it came in at $1.55 million, down 8.3% from FY2024.

  • Depreciation & Amortization (CF) has declined in each of the last three years, with a five-year compound annual growth rate of -8.4% (FY2020 to FY2025).
  • Going back by year, Depreciation & Amortization (CF) was $1.7 million in FY2024 (-27.6%), $2.34 million in FY2023 (-2.5%), $2.4 million in FY2022 (+2.0%) and $2.36 million in FY2021 (-2.1%).
  • The Q2 2026 figure represents the highest quarterly Depreciation & Amortization (CF) since Q4 2023.
  • Year-over-year, Depreciation & Amortization (CF) has increased for three consecutive quarters, with an average decline of 2.7% over the last eight quarters.
  • The fastest year-over-year change in Depreciation & Amortization (CF) over five years came in Q1 2022 (growth of 110.3%), and the weakest in Q3 2024 (a decline of 33.8%).
  • Business Quant data shows KNSA's Depreciation & Amortization (CF) at $468,000 (Q1 2026), $467,000 (Q4 2025) and $384,000 (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.96 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 194.00 Mn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 599.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 1.93 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 1.11 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 98.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 1.62 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 56.50 Mn
10 Kiniksa Pharmaceuticals International 11.64 Bn 10.38 Bn 220.03 Mn 472,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 472,000.00
Mar 31, 2026 468,000.00
Dec 31, 2025 467,000.00
Sep 30, 2025 384,000.00
Jun 30, 2025 358,000.00
Mar 31, 2025 345,000.00
Dec 31, 2024 400,000.00
Sep 30, 2024 399,000.00
Jun 30, 2024 430,000.00
Mar 31, 2024 466,000.00
Dec 31, 2023 540,000.00
Sep 30, 2023 603,000.00
Jun 30, 2023 602,000.00
Mar 31, 2023 596,000.00
Dec 31, 2022 602,000.00
Sep 30, 2022 493,000.00
Jun 30, 2022 651,000.00
Mar 31, 2022 656,000.00
Dec 31, 2021 668,000.00
Sep 30, 2021 658,000.00
API Access

Kiniksa Pharmaceuticals International Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=KNSA&period=max&api_key=YOUR_API_KEY